← Leaderboards
Kari E Hacker
New York University School Of Medicine
$1,374,992
Attributed
$2,749,984
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $703.3K · FY2021–24$1M$750K$500K$250K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$2,749,984 · 1
By mechanism
R01$2,749,984 · 1
Top collaborators
- Benjamin G. Neel4 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Howard S Hochster$9,390,994
- Kwok Kin Wong$31,472,345
- Tony Tung Huang$10,994,698
- Benjamin G. Neel$33,134,772
- Michelle Krogsgaard$10,631,626
Others in their field
Other Emerging Leaders on “Doxorubicin”
- Benedict Shek Hang Law · Weill Medical Coll Of Cornell Univ$4,167,074
- Ozgur Sahin · Medical University Of South Carolina$3,925,035
- Tzu-Yin Lin · Theranostec, Inc.$3,924,751
- Aarti Asnani · Beth Israel Deaconess Medical Center$3,921,462
- Ashley Smuder · University Of Florida$3,752,771
- Hui-Ming Chang · University Of Missouri-Columbia$3,417,937
Research focus
DoxorubicinEngineeringAnti-Pd-L1AffectApoptosisAnti-Ctla4BehaviorBiologicalBiologyBrca1 GeneBrca2 GeneCancer BiologyCcne1 GeneCell BehaviorCellsCell TransformationCessation Of LifeChemokineChemotherapyCredentialingCxcl10 GeneCytokineDisease ResistanceEvent
Grant awards (4)
New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma$668,154
R01 · FY2024 · CA
New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma$689,255
R01 · FY2023 · CA
New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma$689,255
R01 · FY2022 · CA
New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma$703,320
R01 · FY2021 · CA